Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant palbociclib versus capecitabine-based intensive therapy in HR-positive/HER2-negative non-pCR breast cancer after neoadjuvant chemotherapy
ChiCTR2000037206Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by Changhai Hospital. Primary endpoint: invasive disease-free survival. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000037206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037206.